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The yellow fever (YF) 17D virus is one of the most successful vaccines developed to date. Its use has been estimated to
be over 400 million doses with an excellent record of safety. In the past 3 years, yellow fever vaccination was intensified in
Brazil in response to higher risk of urban outbreaks of the disease. Two fatal adverse events temporally associated with YF
vaccination were reported. Both cases had features similar to yellow fever disease, including hepatitis and multiorgan failure.
Two different lots of YF 17DD virus vaccine were administered to the affected patients and also to hundreds of thousands
of other individuals without any other reported serious adverse events. The lots were prepared from the secondary seed,
which has been in continuous use since 1984. Nucleotide sequencing revealed minor variations at some nucleotide positions
between the secondary seed lot virus and the virus isolates from patients; these differences were not consistent across the
isolates, represented differences in the relative amount of each nucleotide in a heterogeneous position, and did not result
in amino acid substitutions. Inoculation of rhesus monkeys with the viruses isolated from the two patients by the intracerebral
(ic) or intrahepatic (ih) route caused minimal viremia and no clinical signs of infection or alterations in laboratory markers.
Central nervous system histological scores of rhesus monkeys inoculated ic were within the expected range, and there were
no histopathological lesions in animals inoculated ih. Altogether, these results demonstrated the genetic stability and
attenuated phenotype of the viruses that caused fatal illness in the two patients. Therefore, the fatal adverse events
experienced by the vaccinees are related to individual, genetically determined host factors that regulate cellular suscepti-
bility to yellow fever virus. Such increased susceptibility, resulting in clinically overt disease expression, appears to be
extremely rare. © 2001 Academic Press
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INTRODUCTION
Brazil, like several other countries in South America,
has an extensive Amazonian forest region in which jun-
gle yellow fever (YF) is endemic and a coastal zone in
which yellow fever does not occur (Robertson et al., 1996;
Vasconcelos et al., 1997). The boundary between these
zones may be affected by periodic expansions in
epizootic activity. The densely populated coastal zone
has become reinfested with the urban vector, Aedes
aegypti, and is thus receptive to the introduction and
spread of YF from the endemic area (Vasconcelos et al.,
1997, 1999).
Between 1998 and 2000, yellow fever cases occurred
over a very wide area in Brazil and expanded beyond
traditional boundaries of the endemic zone, to involve the
western regions of three states, Minas Gerais, Sa˜o
Paulo, and Bahia States. Due to the upsurge in yellow
fever activity in the endemic area and the increasing
mobility of the human population, there have been recent
imported cases of yellow fever in the coastal zone, e.g.,
Rio de Janeiro and the interior of Sa˜o Paulo State, re-
newing concerns about reurbanization (Vasconcelos et
al., 2001a). The risk of urban yellow fever is enhanced by
the expanding distribution and density of Ae. aegypti,
which now include all 27 states of the country (Travassos
da Rosa et al., 2000).
The YF 17D virus is one of the most successful vac-
cines developed to date. It has a well-defined and effi-
cient production methodology, with strict quality control
including monkey neurovirulence testing. It is inexpen-
sive, and a single dose provides long-lasting immunity in
100% of vaccinated individuals. Its use has been esti-
mated to be over 400 million doses with an excellent
record of safety. Only 21 cases of postvaccinal enceph-
alitis have been recorded after seed lot system imple-
mentation in 1945, with incidence on very young infants
1 To whom correspondence and reprint requests should be ad-
dressed at Fundac¸a˜o Oswaldo Cruz, Departamento de Bioquimica e
Biologia Molecular, Avenida Brasil 4365, Manguinhos, 21045-900 Rio
de Janeiro, RJ, Brazil. Fax: 55 21 590 3495. E-mail: rgaller@
gene.dbbm.fiocruz.br.
Virology 290, 309–319 (2001)
doi:10.1006/viro.2001.1168, available online at http://www.idealibrary.com on
0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
309
(9 months, rate of 0.5–4/1000, and 9 months, 1/8
million; Monath, 1999).
In 1998 and 1999, yellow fever vaccination was inten-
sified in Brazil in response to higher risk of urban out-
breaks of the disease. Approximately 34 million doses
have been applied since 1998. Increased surveillance for
vaccine-associated adverse events was also imple-
mented in Brazil during this interval. The vaccine, man-
ufactured by BioManguinhos, Rio de Janeiro, contains
the 17DD substrain and has been in continuous use for
over 60 years. This substrain was derived from 17D virus
by separate downstream passages starting with pas-
sage 195. It is used in Brazil, while the 17D-204 vaccine
is employed in other countries (reviewed in Monath,
1999).
Vaccination with 17DD virus led to three reports of
adverse reactions in Brazil, all of neurological origin as
were the ones previously reported after vaccination with
other 17D substrains mainly 17D-204. There were one
case of encephalitis and two of paralysis, for an inci-
dence of 0.09 per million (Ministry of Health, unpublished
data), which is not different from the historical incidence
of postvaccinal encephalitis—an expected, rare compli-
cation of yellow fever vaccination.
In October 1999 and February 2000 two fatal adverse
events temporally associated with YF vaccination oc-
curred in Goiaˆnia (Goia´s State) and Americana (Sa˜o
Paulo State). Details of these cases have been described
elsewhere (Vasconcelos et al., 2001b). Both cases had
features similar to yellow fever disease, including hepa-
titis and multiorgan failure. Two different lots of YF 17DD
virus vaccine (lots 29Z and 88Z) were administered to the
affected patients. The same lots were also administered
to hundreds of thousands of other individuals without
any other reported serious adverse events. The lots were
prepared from the secondary seed (102/84, passage
285), which has been in continuous use since 1984. A
third fatal case occurred in Santos, Sa˜o Paulo State, in
May 1999. The clinical details of this are not well docu-
mented, and the vaccine lot used is unknown.
Virus was recovered from all three cases from blood or
postmortem tissues and identified by PCR amplification
and immunostaining as YF virus. Partial nucleotide se-
quence analyses showed that in at least two cases,
Goiaˆnia and Americana, the viruses corresponded to the
YF 17DD vaccine (Vasconcelos et al., 2001a).
The main objective of the molecular studies described
here was to define whether any genetic changes oc-
curred in the virus during its production and/or multipli-
cation in the vaccinees that could explain the fatal ad-
verse events. These studies were complemented by the
analysis of the viral phenotype after inoculation of rhesus
monkeys with viruses recovered from two of the cases.
RESULTS
Nucleotide sequence determinations
Figure 1 depicts the passage history of each virus
used in the molecular analysis of YF 17DD strains asso-
ciated with serious adverse reactions in humans.
The genomic sequence of the secondary seed lot
virus, 102/84, was derived entirely from RNA extracted
FIG. 1. Passage history of YF 17DD viruses.
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directly from the reconstituted vial. The seed is used to
inoculate embryonated eggs for vaccine production in
the YF vaccine manufacturer laboratory. One Vero cell
passage was also carried out to examine the influence of
this passage on the 3 end sequence stability.
The intermediate viruses between the secondary seed
lot and the viruses isolated from patients are the vaccine
lots 29Z and 88Z. The vaccine lot used in the Santos case
is unknown. The 29Z lot virus structural region (nt
1–2475) and the 3 end (10,452–10,860) were sequenced
directly from the reconstituted material of the original
vaccine vial. For 88Z lot virus part of the structural region
(nt 1659–2507) and its 3 end (nt 10,450–10,862) were
sequenced from virus present in the vaccine vial sus-
pension, whereas most of the structural region (nt
1–2495) sequence was derived from virus of a Vero cell
passage.
The complete nucleotide sequence of Goiaˆnia virus
genome was derived directly from liver suspension ma-
terial. Approximately 75% (8130 nt) of the genome was
sequenced on both strands. This sequencing was ex-
tended to a Vero cell-passaged virus genome to obtain
complementary strand sequence and to analyze its ex-
treme 3 end (nt 14–2434, 2885–3330, 3627–4530, 5552–
6275, 6830–8650, 8850–10,562; Table 1). Further analy-
ses of the 3 end sequence included viruses from differ-
ent organs (heart, spleen) of the same patient. These
viruses were available as tissue suspension and as
C6/36 cell culture supernatants with one and two pas-
sages, respectively. For all of these viruses, the nucleo-
tide sequences were determined at the 3 end (nt
10,450–10,862; Fig. 1).
For the Americana case, the identity of the infecting
virus was determined by sequencing the E gene of viral
RNA present in serum. The complete genome sequence
(except for a gap in the NS5 gene (nt 8188–8343) was
determined for virus recovered from a liver suspension
virus that had been passaged once in C6/36 cells. Ap-
proximately 56% (6047 nt) of the genome sequence was
on both strands. To complement this sequence, the virus
was first isolated from liver tissue by mouse brain inoc-
ulation followed by a single passage in Vero cells. The
whole structural region (nt 1–2453) plus the 3 end and
the NS5 gap (nt 8034–8573) of this virus was sequenced.
Virus from the Santos case was isolated from serum
by intracerebral (ic) inoculation of suckling mice. The
complete genomic sequence was determined from viral
RNA extracted from Vero cells infected with the suckling
mouse brain passage.
Considering all sequences available, the 102/84,
Americana, Goiaˆnia, and Santos viruses had their com-
plete genome as cDNA sequenced on both strands.
TABLE 1
Summary of Nucleotide Sequence Differences among YF 17DD Viruses
Nucleotidea Codona Genea Asibib
17DDc
original
Secondary
seed 102/84 Lot 29Z Lot 88Z Americana Goiaˆnia Santos
Amino acid
change
1003 10 E T T T/C T/C T/C T/C T T/C None
1887 305 E C T T T T T, T/Cd T T F 3 S
2110e 379 E G A G G G G G G None
2356 f 461 E C T C C C C C C None
2677 853 NS1 C C/Tg T nd nd T T T None
4523 1469 NS2B C C/Tg C/T nd nd C C/T C/T None
5362h 1748 NS3 C A C nd nd C C C None
9988 3294 NS5 C C C/T nd nd C/T C C/T None
10,174 3352 NS5 A A A/G nd nd A A A/G None
10,243 3375 NS5 G A/Gg G nd nd G G G None
10,367 — 3 NC T C/Tg T nd nd T T T —
10,675 — 3 NC A A A/G A/G A/G A/G A/G A/G —
10,841 — 3 NC G G G G G G G i G —
10,842 — 3 NC G G G G G G G i G —
a Rice et al., 1985.
b Hahn et al., 1987.
c GenBank Accession No. U17066.
d T, unpassaged virus recovered from serum; T/C, liver virus passaged in mouse brain and Vero cells.
e YF 17D 204 ATCC (X03700), 17D-204 France (X15062), and 17D-213 WHO (U17067) showed nucleotide G at this position.
f YF 17D 204 viruses (ATCC, France, and WHO) showed T at this position.
g Original sequence as reported by Post et al., 1992, and Duarte dos Santos et al., 1995, shown in bold. Reexamination of the sequence 2000
revealed heterogeneity as shown. nd, not determined.
h YF 17D 204 ATCC showed C, 17D-204 France showed A, and 17D-213 WHO showed T at this position.
i Liver virus, unpassaged, showed nucleotide C at these positions; however, Vero 1 passage of the liver isolate virus, as well as unpassaged spleen
and heart virus, revealed the sequence to be G.
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A summary of the comparative sequence analysis is
shown in Table 1. Differences are shown between the
viruses listed and the original published 17DD sequence
(GenBank Accession No. U17066, originally described by
Post et al., 1992, and Duarte dos Santos et al., 1995). The
original 17DD sequence was performed on a vaccine lot
at passage 286 equivalent to vaccine lots 29Z and 88Z.
The secondary seed lot virus corresponds to passage
285.
The initial sequencing of the Americana and Goiaˆnia
isolates had found a number of inconsistent differences
with the original 17DD sequence (Table 1). Therefore, we
first concentrated on determining the complete nucleo-
tide sequence of the BioManguinhos 102/84 secondary
seed lot virus genome and on the heretofore undefined
Santos case virus. If no differences could be found be-
tween the secondary seed and the viruses isolated from
the cases, there would be little value in sequencing the
intermediate vaccine lot viruses. As described below this
was indeed the case and this is the reason for the limited
sequencing carried out on the vaccine lot viruses.
Comparison of BioManguinhos 102/84 secondary
seed and the original 17DD sequence
The original sequence of 17DD was reexamined in its
original files and displayed heterogeneity at nt 2677,
4523, 10,243, and 10,367 (Table 1). The original published
sequence is shown in bold; the other nucleotides at
these positions found as a minority population are also
shown. The importance of this reexamination will be-
come apparent when considering the sequence data for
the cases with adverse events.
A comparison of the secondary seed and the original
17DD sequence revealed differences at 2110 and 2356 (E
gene) and 5362 (NS3) none of which resulted in an amino
acid change. Several other positions displayed hetero-
geneity, that is, two nucleotides were detected by se-
quencing. This suggests the coexistence of viral popu-
lations bearing one or the other nucleotide at that par-
ticular position. When a particular heterogeneity was not
observed in one virus, one of the nucleotides of that
heterogeneous position was always present (at posi-
tions 1003, 2677, 4523, 9988, 10,174, 10,243, 10,367, and
10,675). Therefore, these variations cannot be consid-
ered mutations. Moreover, neither nucleotide in the het-
erogeneous mixture at a given position resulted in an
amino acid change.
The nucleotide (A) at position 2110 in the original
sequence represents one of the differences originally
defined between 17DD and 17D-204 substrain vaccines,
which have a G at this position (Post et al., 1992). How-
ever, we found the BioManguinhos secondary seed to
have a G at this position and thus to be identical to all
17D-204 substrain vaccines and wild-type parental Asibi
virus (Table 1). Since the original 17DD sequence was
performed with virus derived from the same secondary
seed, it is possible that the original sequence may con-
tain an error and that there is no difference between any
yellow fever vaccine and wild-type virus at this position.
The nucleotide (T) at position 2356 in the original 17DD
sequence represents one of the differences originally
defined between all vaccine viruses and Asibi virus (Post
et al., 1992; Galler et al., 1998). We found the BioMan-
guinhos secondary seed sequence (as well as the vac-
cine lots and patient isolates) to have a change (T3 C)
at this nucleotide, representing a reversion to the wild-
type Asibi sequence (Table 1). However, since the orig-
inal 17DD sequence was performed with virus derived
from the same secondary seed, it is possible that the
original sequence is in error and that 17DD vaccine does
in fact have the wild-type sequence at this position.
Since both 17DD and 17D-204 vaccines are attenuated,
and since the nucleotide difference occurs at the third
position in the codon and does not result in an amino
acid change, it is unlikely that nt 2356 is relevant to
attenuation/virulence or that it plays a role in the adverse
events.
The nucleotide (A) at position 5362 (NS3) in the origi-
nal 17DD sequence was found to be C in the secondary
seed, the vaccine lots, and the patients’ isolates. How-
ever, there is considerable variability across yellow fever
vaccine strains at this nucleotide (Table 1). These
changes do not result in an amino acid change and are
not involved in virulence/attenuation.
Differences between the BioManguinhos secondary
seed 102/84 and the viruses recovered from patients
with adverse events
There were no consistent differences between the
secondary seed and virus isolates from patients. The
secondary seed and Santos isolate were identical. The
secondary seed differed from either Americana or
Goiaˆnia strains but never from both strains at nucleo-
tides 1003, 4523, 9988, and 10,174 (Table 1). At these
positions, the seed and patient viruses displayed heter-
ogeneity of the same nucleotides, and therefore these
differences cannot be considered mutations. None of
these changes encoded an amino acid substitution.
The only notable exception is a difference between the
secondary seed and the Americana patient virus at nt
1887. The initial sequence of liver (C6/361) and unpas-
saged serum virus revealed no difference from the sec-
ondary seed at nt 1887 (T). However, the sequence of the
Americana strain isolated from liver and passaged once
in mouse brain and once in Vero cells revealed a minor
heterogeneity (T/C) at this position. Based on the chro-
matogram, it was estimated that the C nucleotide at
position 1887 represents only 10% of the total in the
heterogeneous mixture. The C nucleotide was not seen
in the secondary seed or in the vaccine lot 29Z used to
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immunize the patient. Therefore, the heterogeneity de-
tected probably resulted from selection or mutation dur-
ing the additional mouse brain and cell culture passage
of the virus rather than mutation during replication in the
patient. Interestingly, virus containing the C nucleotide at
position 1887 constitutes a reversion to the parental
Asibi virus sequence and does result in an amino acid
substitution (phenylalanine 3 serine) at residue 305 of
the E protein. E305 has been suspected to be an impor-
tant virulence factor (at least for neurotropism), since
virus recovered from a fatal case of postvaccinal enceph-
alitis contained a mutation at a juxtaposed amino acid
(E303) (Jennings et al., 1994). Other studies have shown
this region of the E protein to contain important neuro-
virulence determinants. For example, Japanese enceph-
alitis virus selected for resistance to binding brain cell
membranes contained a mutation at E306 and had an
attenuated phenotype (Ni and Barrett, 1998).
It is unlikely that the mutation at nt 1887/E305 in the
passaged virus from the Americana case is related to the
adverse event in this case for the following reasons: (a)
it is not seen in the Goiaˆnia case (or Santos case); (b) it
is not seen in the sequences from serum (unpassaged)
or from liver (passaged in C6/36 cells); (c) it is present in
the mouse brain  Vero passage material only as a
minority subpopulation, i.e., approximately 10% of the
total virus present; and (d) the virus containing the het-
erogeneity was inoculated into rhesus monkeys by either
route, ic or intrahepatic (ih), and yet no clinical signs
were observed (see below).
Differences between the BioManguinhos secondary
seed 102/84 and the vaccine lots used to vaccinate
the cases
No differences were found between the structural
genes of the 102/84 seed and vaccine lots 29Z and 88Z
(Table 1). Since the NS genes did not differ significantly
across the secondary seed and the patient isolates, the
complete sequences of the vaccine lots were not deter-
mined.
Observations on experimental infections of rhesus
monkeys with YF 17DD 102/84, Goiaˆnia, and
Americana viruses
To further confirm that the viruses isolated from the
Americana and Goiaˆnia cases were in fact vaccine vi-
ruses without any altered phenotypic properties as pre-
dicted from the nucleotide sequence data we designed a
protocol to inoculate a limited number of healthy rhesus
monkeys by the ic or ih route and examined the outcome
of the experimental infections. These results are shown
in Tables 2 and 3.
Febrile response. All animals inoculated via ic devel-
oped fever equal or above 40.0°C (Table 2). The onset of
fever in these animals was on day 8 in four of nine
animals, increasing to six of nine animals on day 9; four
of nine on day 10; three of nine on days 11, 12, and 13;
and two of nine on days 14 and 15. During this interval in
which animals more often developed fever, we observed
9 days of fever for animals inoculated with each virus,
102/84, Goiaˆnia, and Americana. The onset of fever does
TABLE 2
Recorded Parameters for the Monkey Safety Test
Virus Route Monkey
Days
(T  40°C)
Clinical
score
Discriminator
areas Target area
Discriminator plus
target areas
Seroconversion titer
Pre Post
Goiaˆnia ic 13 4 0 0.03 1.0 0.51 1:32 1:13,182
ic 17 1 0 1.16 2.0 1.58 1:32 1:5248
ic 60 4 0 0.41 2.0 1.20 1:32 1:6761
ih 5 1 0 0.0 0.0 0.0 1:32 1:16,218
ih 15 1 0 0.0 0.0 0.0 1:32 1:3802
ih 20 0 0 0.0 0.0 0.0 1:32 1:32,768
Americana ic 9 5 0 0.46 1.0 0.73 1:32 1:3715
ic 11 1 0 0.12 1.0 0.56 1:32 1:5012
ic 42 6 0 0.62 1.5 1.06 1:32 1:32,768
ih 3 0 0 0.0 0.0 0.0 1:32 1:4898
ih 35 0 0 0.0 0.0 0.0 1:32 1:7744
ih 56 2 0 0.0 0.0 0.0 1:32 1:4571
102/84 ic 7 3 0 0.68 2.0 1.34 1:32 1:32,768
ic 46 3 0 0.45 1.0 0.72 1:32 1:4677
ic 50 3 0 0.24 1.5 0.87 1:32 1:6166
ih 1 1 0 0.0 0.0 0.0 1:32 1:9332
ih 19 0 0 0.0 0.0 0.0 1:32 1:3715
ih 44 0 0 0.0 0.0 0.0 1:32 1:2691
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not differ with regard to the viruses, as two animals
inoculated with 102/84 were feverish on days 8, 9, and
10, and for Goiaˆnia and Americana viruses, a single
animal had fever on day 8 and two on day 9.
Fewer monkeys inoculated ih developed fever. From
the animals inoculated ih, monkey 56 presented with
fever on the 4th and 10th days but not on other time
points. Other animals (1, 5, and 15) had fever exclusively
on days 17, 18, and 27, respectively.
Viremia. The viremia detected in the sera of monkeys
during the first 7 days postinoculation is shown in Table
3. Circulating virus could be detected in all animals
inoculated ic and in seven of nine animals inoculated ih
(exceptions being one monkey in the secondary seed lot
102/84 and one monkey in the Goiaˆnia group). The total
number of days of detectable viremia for animals inocu-
lated ic was 21 in contrast to only 14 days for animals
inoculated ih.
All viremias were brief and low level as indicated by
mean peak titers and mean duration (Table 3). Goiaˆnia
and 102/84 viruses had similar magnitudes of viremia
after ic inoculation (1.3 log10 PFU/ml), whereas a some-
what higher mean peak titer was observed for Ameri-
cana virus (1.9 log10 PFU/ml). After ih inoculation the
same profile was observed, with the values for Goiaˆnia
(1.5 log10 PFU/ml) and 102/84 (1.6 log10 PFU/ml) viruses
being similar and a higher titer for Americana virus (2.0
log10 PFU/ml). The highest viremia noted was in monkey
35, inoculated ih with Americana virus, which reached
2.28 log10 PFU/ml on the fourth day pi. Of all animals
inoculated ic another monkey (11) inoculated with Amer-
icana virus also had the highest viremia (2.2 log10 PFU/
ml) on the third day pi.
The mean duration of viremia was the same for all
animals inoculated ic regardless of the virus (2.3 days,
Table 3). Upon ih inoculation with Goiaˆnia and 102/84
viruses, duration of viremia averaged 1.5 days but it was
longer in animals given Americana virus (2.7 days).
Antibody response. All animals developed neutralizing
antibodies 30 days after YF virus inoculation as indicated
by the results of plaque reduction neutralization tests
(Table 2). Titers varied from 1:3715 to more than 1:32,768.
There is no evident difference in seroconversion titers to
any virus irrespective of the dose and route.
Clinical findings. No clinical signs of any magnitude
were noted along the 30 days of observation p.i. by either
route with any of the viruses (Table 2). The facts that
most animals displayed viremia and all specifically se-
roconverted to YF in neutralization tests confirm that the
animals were indeed infected by the respective virus
inoculated. Even those animals that had the highest
viremia did not present any overt clinical signs.
Clinical chemistry analysis included the analysis of
serum transaminases (AST/ALT), total bilirubin, alkaline
phosphatase, lactate dehydrogenase, -glutamyltrans-
ferase, creatinine, blood urea nitrogen, total protein, al-
bumin, and globulin. Hematological analyses included
total and differential blood cell counts (polysegmented
neutrophils, band cells, lymphocytes, monocytes, eosin-
ophils, and basophils), hemoglobin concentration, plate-
TABLE 3
Viremia in Rhesus Monkeys Inoculated by the Intracerebral (ic) or Intrahepatic (ih) Routes with Yellow Fever 17DD Isolates from Fatal
Vaccine-Associated Cases and the 17DD Secondary Seed
Virus/route Monkey
Viremia (log10 PFU/ml) by postinoculation days Mean
Range1 2 3 4 5 6 7 Peak titera (SD) Durationb (SD)
Goiaˆnia—ic 13 0.9 0.9 0.9 0.90 1.38 0.9 0.9
17 0.9 0.9 1.38 1.5 1.20 0.9 0.9 1.3 0.3 2.3 1.1 0.9–1.38
60 0.9 0.9 0.9 0.90 0.9 0.9 0.9
Goiaˆnia—ih 05 0.9 0.9 1.68 0.9 0.9 0.9 0.9
15 0.9 0.9 0.9 0.9 0.9 0.9 0.9 1.5 0.2 1.5 0.7 1.2–1.68
20 0.9 0.9 1.38 1.2 0.9 0.9 0.9
Americana—ic 09 0.9 0.9 0.90 1.90 0.9 0.9 0.9
11 0.9 0.9 2.20 1.60 1.80 0.9 0.9 1.9 0.2 2.3 1.5 0.9–2.20
42 0.9 0.9 0.9 0.9 1.74 0.9 0.9
Americana—ih 03 0.9 1.90 1.60 1.20 0.9 0.9 0.9
35 0.9 0.9 2.18 2.28 1.74 0.9 0.9 2.0 0.4 2.7 0.6 1.20–2.28
56 1.38 1.85 0.9 0.9 0.9 0.9 0.9
17DD—ic 07 0.9 0.9 1.60 0.90 0.9 0.9 0.9
46 0.9 0.9 0.9 0.9 0.90 0.9 0.9 1.3 0.4 2.3 1.5 0.9–1.60
50 0.90 1.50 0.9 1.50 1.50 0.9 0.9
17DD—ih 19 0.9 1.20 0.9 0.9 0.9 0.9 0.9
44 0.9 0.9 0.9 0.9 0.9 .9 0.9 1.6 0.5 1.5 0.7 0.9–1.98
1 0.9 0.9 1.98 0.9 0.9 0.9 0.9
a Log10 PFU/ml.
b Days.
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let counts, and hematocrit. Samples from days 1 (prein-
oculation), 2, 4, 6, and 31 were analyzed. None of these
tests did suggest any alteration in the physiology of the
inoculated animals (data not shown).
All animals inoculated ic, except monkey 9, lost weight
at the end of the 30-day observation period. None of
them had signs of diarrhea or anorexia. The loss aver-
aged 506 g for animals inoculated with 102/84 virus,
320 g for animals with Americana virus, and 366 g for
animals with Goiaˆnia virus. Animals inoculated ih with
102/84 and Goiaˆnia viruses gained weight (average of 40
and 120 g, respectively) but animals which received the
Americana virus lost an average of 126 g (data not
shown).
Histological findings. All nine rhesus monkeys inocu-
lated ic with Goiaˆnia, Americana, and 102/84 seed lot
viruses developed histological lesions (Table 2). None of
the animals inoculated ih developed any histological
lesions in either the CNS (Table 2) or the extraneural
organs, including liver, kidney, adrenals, heart, spleen,
and lung (data not shown). No lesions in these visceral
organs were observed for the animals inoculated ic. For
all animals, there were no abnormalities in any organs
that could suggest damage or impaired function. In this
regard immunostaining analysis employing hyperim-
mune sera (ATCC) and a YF-specific monoclonal anti-
body did not reveal any YF virus antigen in any of the
tissues above of animals infected with a virus as it did for
the positive control tissue from another monkey which
had died as a consequence of direct inoculation of an
experimental YF 17D virus (Marchevsky et al., 1995). A
second positive control for the immunostaining assays
was liver histological sections from the Goiaˆnia case
(data not shown). In addition, liver biopsies of all 18
animals at the 10th day postinoculation, regardless of
inoculation route, were analyzed for histological lesions,
immunostaining for viral antigen, and viral isolation. All
tests were negative as there were no signs of liver tissue
damage, no staining for viral proteins, nor isolation of
virus.
As proposed by Levenbook et al. (1987) the target area
in the rhesus monkey CNS for several vaccine viruses is
the substantia nigra. In this study the substantia nigra
presented with the highest histological scores for the
monkeys inoculated ic with all three viruses. Based on
the individual values shown in Table 2, 102/84 virus had
an average score in this area of 1.5, with 1.67 for Goiaˆnia
and for 1.16 Americana virus. In five complete neuroviru-
lence tests for the 17DD 102/84 seed lot virus the aver-
age target area score was 1.49 (R. S. Marchevsky and R.
Galler, in preparation).
Among the discriminator areas in the CNS, the puta-
men, globus pallidus, and nucleus caudatus were the
areas more affected but the lesion scores were never
above 2 with any of the viruses. The only exception was
a grade 3 lesion on the left side of the nucleus caudatus
of monkey 17 inoculated ic with Goiaˆnia virus. This ani-
mal also had the highest combined target/discriminatory
score (1.58; Table 2) but yet no clinical signs were noted.
The average discriminator area score for 102/84 virus
was 0.45, for Goiaˆnia 0.53, and for Americana 0.40, val-
ues which are very close to each other and to the
average value observed for 102/84 across five other full
neurovirulence tests (0.67; R. S. Marchevsky and R. Gal-
ler, in preparation).
The degree of neurovirulence of a given virus is the
average of combined target/discriminator areas scores
of all the monkeys. For 102/84 virus this combined score
was 0.97, for Goiaˆnia 1.09, and for Americana 0.78. The
values for the combined neurovirulence scores in five
complete tests with 102/84 virus varied between 0.96 and
1.37 with an average of 1.07.
DISCUSSION
It is important to underscore the limitations of genome
analysis in this investigation. A limitation is that yellow
fever vaccine is not biologically cloned and is known to
be a mixture of multiple subpopulations of virions reflect-
ing the quasispecies nature of flaviviruses. Molecular
analysis results in a consensus sequence and is rela-
tively insensitive for the demonstration of minority virus
subpopulations. Only when present at a concentration of
10–20% will such subpopulations be detected. In fact,
this was the case in the current analyses, with hetero-
geneity in the nucleotide sequence demonstrated at mul-
tiple positions. The underlying assumption is that selec-
tion of a mutation responsible for an increased virulence,
leading to death of the infected host, would result in the
altered genotype being the majority species in the con-
sensus sequence. A second assumption is that one or
more amino acid changes would be required for a sig-
nificant change in virulence, although it is theoretically
possible that silent changes could alter secondary struc-
ture and biological properties of the virus.
No consistent sequence changes were noted between
the BioManguinhos secondary seed virus and the vi-
ruses isolated from the Americana, Goiaˆnia, and Santos.
Minor variations at nucleotides 1003, 4523, 9988, and
10,174 were found between the secondary seed and the
patient isolates; these differences were not consistent
across the patient isolates, represented differences in
the relative amount of each nucleotide in a heteroge-
neous position, and did not result in amino acid substi-
tutions. These variations are not related to the adverse
events.
At one position (nt 1887/E305), a mutation was de-
tected in the Americana virus, resulting in an amino acid
change to the wild type (Asibi sequence). However, this
change probably occurred during laboratory passage of
the isolate; it was not detected in unpassaged virus and
was a minority subpopulation in the passaged strain. It
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was not observed in the Goiaˆnia and Santos cases. It is
not considered relevant to the adverse event in this case.
Virulence is defined by the ability of the virus to cause
in an experimental animal model clinical illness, clinical
laboratory abnormalities, histopathology of visceral and
neural tissues, and higher viremia compared to a refer-
ence vaccine strain. Rhesus monkeys are exquisitely
sensitive to infection with YF viruses and have been
developed as a system for the analysis of YF 17D virus
attenuation (Monath, 1999). The histopathologic scoring
methodology for neurotropism (Levenbook et al., 1987)
was incorporated into the biological standards for YF
17D vaccines (WHO, 1995).
In the experimental infection of rhesus monkeys by the
intracerebral route with 102/84, Goiaˆnia, and Americana
viruses, monkey serum viremia does not appear to differ
among the viruses. Americana virus apparently caused
longer viremia than the other viruses by the ih route of
inoculation. However, the serum viremia observed in
monkeys inoculated ih or ic with all viruses are of the
same magnitude (1–2 log10 PFU/ml). The definition put
forward by the WHO (1995) of viscerotropism of 17D virus
limits the amount of circulating virus to below 500 mouse
LD50/0.03 ml for all (10 of 10) sera and 100 LD50/0.03 ml
in 1 of 10 monkey sera at 1:10 dilution. In this regard, the
highest viremia observed (2.28 log10 PFU/ml for monkey
35, inoculated ih with Americana virus, corresponded to
1.14 LD50/0.03 ml and therefore was well below the es-
tablished limits. In addition, the range of titers observed
here is similar to that observed for rhesus monkeys
inoculated with attenuated 17D/JE SA-14-14-2 and 17D-
den2 chimeric viruses (Monath et al., 2000; Guirakhoo et
al., 2000).
The absence of clinical signs of infection, no alter-
ations in laboratory markers, CNS histological scores of
animals inoculated ic within the expected range, and
limited viremia suggest an attenuated phenotype of the
viruses recovered from the two Goiaˆnia and Americana
fatal cases similar to that of 17DD 102/84 virus.
It is concluded that the fatal adverse events experi-
enced by the vaccinees are not due to genetic variation
in the YF 17DD vaccine virus. The adverse events may be
related to individual, genetically determined host factors
that regulate cellular susceptibility to yellow fever vi-
ruses. Such increased susceptibility resulting in clini-
cally overt disease expression appears to be extremely
rare. This conclusion is supported by the data that orig-
inated from experimental infection of rhesus monkeys
with viruses derived from the human cases of adverse
events for which the nucleotide sequences had been
determined.
There are many genetically determined factors that
can contribute to the control of virus infection and influ-
ence the outcome of infection that may have led to these
adverse events, such as specific (antibody and T cell
responses) and nonspecific (e.g., interferon system) im-
munity. It has been proposed for alphaviruses that the
endocrine system also can play an important role in
virus-induced pathology due to induction of toxic levels
of stress hormones and proinflammatory cytokines that
can cause excessive tissue damage directly or lead to
immunosupression facilitating virus replication (Trgovich
et al., 1996, 1997). Abnormalities in any of these systems
(that interact in a complex way) may have led to the fatal
outcome in the adverse postvaccination events studied
here. Other genetic determinants may be host cell fac-
tors which are hypothesized to participate in virus ge-
nome replication (Shi et al., 1986). Theoretically, these
proteins, if mutated, could lead to abnormalities in the
virus replication cycle, e.g., accumulation of higher levels
of viral double-stranded RNA intermediates in infected
cells that may result in more pronounced cell death (due
to apoptosis) and tissue damage. Apoptosis itself is a
complex multicomponent cascade and alterations in this
cascade may result in higher than normal reactogenicity
to infection with a certain virus and thus profound pa-
thology. These possibilities require further investigation.
If new adverse cases happen, tissue samples from vic-
tims should be preserved to undertake comprehensive
genetic analysis (e.g., using microarray technology),
which may open new possibilities for making vaccines
safer (via genetic screening) and possibly discover new
genes that play important roles in susceptibility to virus-
induced pathology.
MATERIALS AND METHODS
Cells
Vero cells (ATCC, CCL 81) were maintained in Medium
199 with Earle’s salts, buffered with sodium bicarbonate
and supplemented with 10% fetal bovine serum (FBS)
and antibiotics. C6/36 cells were maintained in Leibo-
vitz’s L-15 medium supplemented with 5% FBS, nones-
sential amino acids, and antibiotics.
Viruses
The virus strains available for study with their passage
history are depicted in Fig. 1. The operating principle was
to sequence viruses at the lowest passage level possi-
ble, in order to avoid mutations or selection of variants
that could occur during laboratory passage. The 102/84
secondary seed and vaccine lots 29Z and 88Z viruses
present in the original vials were reconstituted in 0.5 ml
of sterile water as specified by the manufacturer (Bi-
oManguinhos, Rio de Janeiro, Brazil).
For the Americana case, viral RNA was extracted di-
rectly from patient serum or C6/36 or Vero cell culture
supernatant. The Vero cell passage was carried out with
virus resulting from one passage of patient serum virus
in suckling mouse brain (Fig. 1). The C6/36 cell and
mouse brain passages were made at the Adolpho Lutz
Institute, Sa˜o Paulo, Brazil.
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The Goiaˆnia case virus (GOI 4191) was derived from
tissue suspensions (liver, spleen, and heart). Virus from
liver tissue was passaged once in Vero cells at FioCruz.
Heart and spleen tissue viruses were passaged once
and twice in C6/36 cells, respectively, at the Evandro
Chagas Institute, Bele´m, Brazil.
The Santos case virus, available only as a serum
sample, was isolated by inoculation into suckling mouse
brain (Adolpho Lutz Institute). The resulting virus suspen-
sion was used to inoculate Vero cells (single passage) at
FioCruz (Rio de Janeiro, Brazil).
Viruses were passaged once in Vero cells at a multi-
plicity of infection (m.o.i.) of 0.1–1 PFU/cell and cell cul-
ture supernatant was harvested at 3–4 days p.i. There
was extensive cytophatic effect on the cell monolayers.
The m.o.i. for the infection of Vero cells with tissue
suspension material was not known, as the suspension
(10%) was diluted 1:10 and used for inoculation. The
supernatants were frozen in the presence of 10% sorbitol
as stabilizer. The Vero cell culture supernatants or the
reconstituted material was used directly for RNA extrac-
tion. All Vero cell passages were carried out at FioCruz
on different days so as to avoid any potential cross-
contamination. The 102/84 virus was passaged in Vero
cells at Acambis, Inc.
Complementary DNA synthesis, amplification, and
sequencing
RT, PCR, and sequencing primers were designed using
the YF 17D strain sequence (GenBank Accession No.
K02749) as reference. A Goiaˆnia liver sample was homog-
enized to yield a suspension (10% w/v in 0.75% bovine
serum albumin (Sigma Co.) in phosphate-buffered saline
with antibiotics) and mixed with Trizol LS (Life Technolo-
gies) and RNA was extracted as indicated by the manufac-
turer. Reverse transcription and amplification were carried
out with the GeneAmp RNA/PCR Core kit (Perkin–Elmer). A
total of 14 RT/PCR products were synthesized encompass-
ing nucleotides 1–1064, 940–1798, 1130–1978, 1640–2638,
2361–3387, 3002–4285, 4181–5070, 4979–6324, 6100–7271,
7161–8419, 8300–9346, 9148–9826, 9423–10,345, and
10,166–10,862. PCR products were purified using QIA Quick
PCR Purification kit (Qiagen). RNA from Americana virus
samples was extracted from the serum or from C6/36 cell
culture supernatants using the QIAmp Viral RNA Extraction
kit (Qiagen) and RT/PCR performed with Superscript One-
Step RT-PCR kit (Life Technologies). A total of 13 PCR
products were produced, being 2 (625–1312 and 1220–
2550) on RNA extracted directly from serum and 11 from
C6/36 supernatant (1–1064, 940–1798, 1549–1823, 1823–
3380, 3002–4285, 4181–5070, 4979–6324, 6100–7271, 7161–
8419, 8300–9826, and 9423–10,862). RNA from the second-
ary seed lot virus 102/84, the 29Z and 88Z vaccine lots
present in the original vials as freeze-dried material, all
viruses present in the supernatants of Vero cells, and vi-
ruses from other organs (spleen and heart) either as tissue
suspension or cell culture supernatant were extracted with
Tri Reagent LS (Molecular Research, Inc.) as described by
the manufacturer. Amplification was performed using the
Titan One-Tube RT-PCR System (Roche). Eight cDNAs were
synthesized for each virus 102/84 and Santos: 1–2522,
1900–3487, 2361–5071, 3980–6222, 4780–7418, 6780–8237,
7201–9025, and 8801–10,862. For viruses for which only
limited sequencing was carried out, such as the vaccine
lots and from spleen and heart tissue, cDNAs 1–2522 and
8801–10,862 were prepared. PCR products were purified
from agarose gels (QIAquick Gel Extraction kit; Qiagen) and
sequenced using CEQ dye termination cycle sequencing
(Beckman) followed by reaction product purification with
DyeEx Spin kit (Qiagen) or using dye-terminator rhodamine
sequencing reaction mix (Perkin Elmer). Sequencing was
carried out using a Beckman CEQ 2000 or ABI 377 (Perkin
Elmer) sequenator directly on RT/PCR amplification prod-
ucts without any molecular cloning. Complementary DNA
sequences were evaluated using Sequencher version 3.0
(GeneCodes) software. Nucleotide sequence heterogene-
ities were registered only when a heterogeneous signal
was observed in all chromatograms representing both plus
and minus cDNA strands.
Experimental inoculation of rhesus monkeys
Six groups of three captive-bred healthy rhesus mon-
keys (Macaca mulatta) (13 male and 7 female, weighing
3740 to 7480 g) were obtained from the Primatology
Division (CECAL/FioCruz). Each animal was kept in a
separate cage under controlled environmental condi-
tions (temperature 20–22°C, relative humidity  60%,
and 12 h of artificial light and 12 h of darkness). Animals
were fed twice daily with monkey chow supplemented
with fresh fruits and allowed water ad libitum. All mon-
keys were shown to be free of YF neutralizing antibodies
by plaque reduction neutralization assay.
Virus inoculation. All monkeys were anesthetized by
intramuscular injection of ketamine hydrochloride (20
mg/kg body weight) and inoculated with 0.25 ml of viral
suspension by the intracerebral route into the right fron-
tal cortex or with 0.5 ml by intrahepatic injection. Intra-
cerebral inoculation was carried out by making an inci-
sion through the skin about 2.5 cm above the middle of
the right superior orbital ridge and a hole was drilled
through the skull. Virus solution was inoculated into the
frontal lobe using a 1-ml syringe fitted with a 25-gauge
5
8 needle. For intrahepatic inoculation, the liver was lo-
cated by palpation and percussion and the site of inoc-
ulation was the intercostal space between the fifth and
the sixth ribs over the liver. The liver was inoculated
using a 3-ml syringe fitted with a 1.5-in. 22-gauge needle.
The inoculations were double blind. The investigator
who prepared the virus coded the syringes and had no
knowledge of what each monkey received and those
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inoculating did not know what each syringe contained.
The codes were broken when the histological analyses
were completed.
The viral inocula were back-titrated by plaque assay
on Vero cells. Yellow fever secondary seed lot (YFV 17DD
102/84) was prepared in November 1984 with a titer of
6.47 log10 PFU/ml. Doses were administered with a titer
of 5.49 log10 PFU/0.25 ml (or 61,368 mouse LD50), via ic,
and 5.81 log10 PFU/0.5 ml (128,520 mouse LD50) via ih. For
Goiaˆnia virus the ic dose was 5.03 PFU/0.25 ml (21,278
mouse LD50) and the ih dose was 5.42 log10 PFU/0.5 ml
(52,356 mouse LD50). For Americana virus, the ic dose
was 4.62 log10 PFU/0.25 ml (8318 mouse LD50) and the ih
dose was 4.92 log10 PFU/0.5 ml (16,596 mouse LD50). The
Goiaˆnia and Americana viruses used to inoculate mon-
keys were those resulting from one passage in Vero cells
(Fig. 1). The mouse LD50 was established for YF 17DD
vaccine virus and the values given for Goiaˆnia and Amer-
icana viruses were inferred from their PFU values using
a ratio established at FioCruz with 17DD virus as refer-
ence.
Viremia. Blood samples for the determination of vire-
mia were collected on days 1 through 9 after inoculation.
Serial dilutions (1:3, 1:30, 1:300) of each monkey serum
were titered by plaque assay on Vero cell monolayers
(105 cells/cm2) with 3.5% carboxymethyl cellulose as
overlap in six-well plates. One hundred microliters of
virus suspension was inoculated per well with four wells
per dilution.
Seroconversion. Antibody titers were determined by a
50% plaque reduction test on Vero cells (Stefano et al.,
1999).
Clinical observation. Monkeys were observed for 30
days and rectal temperatures recorded. Temperature
equal to or grater than 40.0°C was considered elevated.
Records of clinical observation were obtained using the
following signs: grade 1  rough coat, not eating; grade
2  high-pitched voice, inactive, slow moving; grade 3 
shaky movements, tremors, uncoordinated movement,
limb weakness; grade 4  inability to stand, limb paral-
ysis, or death. A monkey that died would receive the
score 4 from the day of death until day 30.
Necropsy and histological examination. All 18 animals
were submitted to full necropsy at the end of the obser-
vation period. They were sacrificed by exsanguination
under deep anesthesia. Serum samples were collected
to determine anti-YFV antibodies by plaque-reduction
neutralization assay.
Five levels of the brain and six levels of each of the
lumbar and cervical enlargements were examined. Brain
levels included block I, the corpus striatum at the level of
the optic chiasma; block II, the thalamus at the level of
the mamillary bodies; block III, the mesencephalon at the
level of the superior colliculi; block IV, the pons and
cerebellum at the level of the superior olives; and block
V, the medullar oblongata at the midlevel of the inferior
olives (WHO, 1995).
Numerical scores were given to each hemisection of
the cord and to structures in each hemisection of the
brain. Lesions were scored according to the following
grading system: 1 (minimal), one to three small, focal
inflammatory infiltrates, a few neurons may be changed
or lost; 2 (moderate), more extensive focal inflammatory
infiltrates, neuronal changes or loss that affects no more
than one-third of neurons; 3 (severe), neuronal changes
or loss of 33–90% of neurons, with moderate focal or
diffuse inflammatory infiltration; 4 (overwhelming), more
than 90% of neurons are changed or lost, with variable,
but frequently severe, inflammatory infiltration.
Three separate scores were calculated for each mon-
key: discriminator areas only, target area only, and dis-
criminator plus target areas (Levenbook et al., 1987). The
target area is the substantia nigra, whereas the discrim-
inator areas include the caudate nucleus, globus, palli-
dus, putamen, anterior and medial thalamic nucleus,
lateral thalamic nucleus, and cervical and lumbar en-
largements. A final neurovirulence score was given by
the combination of the scores of both areas (combined
score).
Overall mean scores were calculated for each group
of monkeys as the arithmetic mean of individual monkey
scores for discriminator areas only and for discriminator
plus target areas. For the histological criterion of the
neurotropism test to be satisfied both overall mean
scores for the test monkeys could not be significantly
greater (at the 5% significance level) than the overall
mean scores for the monkeys injected with reference
virus.
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Note added in proof. Recently, Martin and co-workers published an
article (M. Martin, T. F. Tsai, B. Cropp, G. J. J. Chang, D. A. Holmes, J.
Tseng, W. J. Shieh, S. R. Zaki, I. Al-Sanouri, A. F. Cutrona, G. Ray, L. H.
Weld, and M. Cetron, Lancet 358, 98–104, 201) describing four cases of
multiorgan failure associated with YF 17D-204 vaccination and result-
ing in three deaths. Nucleotide sequence analysis suggested that in
one patient, but not in the others, de-novo mutation and selective
amplification of the mutated virus subpopulation was the major cause
of illness.
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